These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 11094065)
61. Transcriptional regulation of topoisomerase II alpha at confluence and pharmacological modulation of expression by bis-benzimidazole drugs. Tolner B; Hartley JA; Hochhauser D Mol Pharmacol; 2001 Apr; 59(4):699-706. PubMed ID: 11259613 [TBL] [Abstract][Full Text] [Related]
62. The cytochrome b5 tail anchors and stabilizes subdomains of human DNA topoisomerase II alpha in the cytoplasm of retrovirally infected mammalian cells. Soltermann A; Ernst A; Leroy D; Stahel RA; Gasser SM Exp Cell Res; 1999 Jun; 249(2):308-19. PubMed ID: 10366430 [TBL] [Abstract][Full Text] [Related]
63. Altered expression and activity of topoisomerases during all-trans retinoic acid-induced differentiation of HL-60 cells. Aoyama M; Grabowski DR; Isaacs RJ; Krivacic KA; Rybicki LA; Bukowski RM; Ganapathi MK; Hickson ID; Ganapathi R Blood; 1998 Oct; 92(8):2863-70. PubMed ID: 9763571 [TBL] [Abstract][Full Text] [Related]
64. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines. Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249 [TBL] [Abstract][Full Text] [Related]
65. ATF is important to late S phase-dependent regulation of DNA topoisomerase IIalpha gene expression in HeLa cells. Son MY; Kim TJ; Kweon KI; Park JI; Park C; Lee YC; No Z; Ahn JW; Yoon WH; Park SK; Lim K; Hwang BD Cancer Lett; 2002 Oct; 184(1):81-8. PubMed ID: 12104051 [TBL] [Abstract][Full Text] [Related]
66. Topoisomerase II-alpha expression in melanocytic nevi and malignant melanoma. Mu XC; Tran TA; Ross JS; Carlson JA J Cutan Pathol; 2000 May; 27(5):242-8. PubMed ID: 10847549 [TBL] [Abstract][Full Text] [Related]
67. Modulation of topoisomerase IIalpha expression by a DNA sequence-specific polyamide. Hochhauser D; Kotecha M; O'hare C; Morris PJ; Hartley JM; Taherbhai Z; Harris D; Forni C; Mantovani R; Lee M; Hartley JA Mol Cancer Ther; 2007 Jan; 6(1):346-54. PubMed ID: 17237293 [TBL] [Abstract][Full Text] [Related]
68. Functional interaction of DNA topoisomerase IIalpha with the beta-catenin and T-cell factor-4 complex. Huang L; Shitashige M; Satow R; Honda K; Ono M; Yun J; Tomida A; Tsuruo T; Hirohashi S; Yamada T Gastroenterology; 2007 Nov; 133(5):1569-78. PubMed ID: 17983804 [TBL] [Abstract][Full Text] [Related]
69. DNA topoisomerase IIalpha and -beta expression in human ovarian cancer. Withoff S; van der Zee AG; de Jong S; Hollema H; Smit EF; Mulder NH; de Vries EG Br J Cancer; 1999 Feb; 79(5-6):748-53. PubMed ID: 10070864 [TBL] [Abstract][Full Text] [Related]
70. Temporal and spatial distribution of DNA topoisomerase II alters during proliferation, differentiation, and apoptosis in HL-60 cells. Sugimoto K; Yamada K; Egashira M; Yazaki Y; Hirai H; Kikuchi A; Oshimi K Blood; 1998 Feb; 91(4):1407-17. PubMed ID: 9454772 [TBL] [Abstract][Full Text] [Related]
71. DNA topoisomerase II-alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer. Nakopoulou L; Lazaris AC; Kavantzas N; Alexandrou P; Athanassiadou P; Keramopoulos A; Davaris P Pathobiology; 2000; 68(3):137-43. PubMed ID: 11174071 [TBL] [Abstract][Full Text] [Related]
72. Decreased DNA topoisomerase II alpha expression and cold-sensitive growth in a mouse mammary cancer cell line resistant to etoposide and doxorubicin. Kawanami K; Nakamura T; Ono M; Kusano T; Okada K; Kikuchi A; Adachi N; Kohno K; Higashi K; Kuwano M Oncol Res; 1996; 8(5):197-206. PubMed ID: 8884812 [TBL] [Abstract][Full Text] [Related]
73. Nitric oxide inhibits topoisomerase II activity and induces resistance to topoisomerase II-poisons in human tumor cells. Kumar A; Ehrenshaft M; Tokar EJ; Mason RP; Sinha BK Biochim Biophys Acta; 2016 Jul; 1860(7):1519-27. PubMed ID: 27095671 [TBL] [Abstract][Full Text] [Related]
74. [Expression of DNA topoisomerases (I, II alpha, II beta) mRNA in etoposide- and mAMSA-resistant cell lines]. Matsumoto Y; Takano H; Nagao S; Iglesias A; Fojo T Gan To Kagaku Ryoho; 1997 Dec; 24(15):2265-9. PubMed ID: 9422071 [TBL] [Abstract][Full Text] [Related]
75. Reduced activity of topoisomerase II in an Adriamycin-resistant human stomach-adenocarcinoma cell line. Son YS; Suh JM; Ahn SH; Kim JC; Yi JY; Hur KC; Hong WS; Muller MT; Chung IK Cancer Chemother Pharmacol; 1998; 41(5):353-60. PubMed ID: 9523730 [TBL] [Abstract][Full Text] [Related]
76. Quantitation of DNA topoisomerase IIalpha and beta in human leukaemia cells by immunoblotting. Padget K; Pearson AD; Austin CA Leukemia; 2000 Nov; 14(11):1997-2005. PubMed ID: 11069037 [TBL] [Abstract][Full Text] [Related]
77. Functional interaction between human topoisomerase IIalpha and retinoblastoma protein. Bhat UG; Raychaudhuri P; Beck WT Proc Natl Acad Sci U S A; 1999 Jul; 96(14):7859-64. PubMed ID: 10393912 [TBL] [Abstract][Full Text] [Related]
78. Enhanced topoisomerase I activity and increased topoisomerase II alpha content in cisplatin-resistant cancer cell lines. Minagawa Y; Kigawa J; Irie T; Kanamori Y; Itamochi H; Cheng X; Terakawa N Jpn J Cancer Res; 1997 Dec; 88(12):1218-23. PubMed ID: 9473741 [TBL] [Abstract][Full Text] [Related]
79. Topoisomerase II-mediated alterations of K562 drug resistant sublines. Zhou R; Wang Y; Gruber A; Larsson R; Castaños-Vèlez E; Liliemark E Med Oncol; 1999 Sep; 16(3):191-8. PubMed ID: 10523799 [TBL] [Abstract][Full Text] [Related]